Vincerx Pharma, Inc.

NasdaqCM VINC

Vincerx Pharma, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024

Vincerx Pharma, Inc. Interest Coverage Ratio is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqCM: VINC

Vincerx Pharma, Inc.

CEO	Dr. Raquel E. Izumi Ph.D.
IPO Date	May 27, 2020
Location	United States
Headquarters	260 Sheridan Avenue
Employees	42
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Key trends

Past 5 years